Botulinum toxin

BTL Industries to Showcase Leading Aesthetic and Muscle Enhancement Innovations at ASLMS 2024

Retrieved on: 
Tuesday, April 9, 2024
Conference, Botulinum toxin, Research, BTL, Quality of life, Society, Product management, Dentistry

This prestigious event brings together top experts, researchers, and practitioners in the field of medical laser applications and energy-based treatments.

Key Points: 
  • This prestigious event brings together top experts, researchers, and practitioners in the field of medical laser applications and energy-based treatments.
  • BTL Industries is set to unveil its latest advancements in aesthetic and muscle enhancement at ASLMS, redefining possibilities for enhancing both form and function.
  • BTL Industries looks forward to engaging with attendees, sharing insights, and fostering collaboration to drive further advancements in medical laser technology and energy-based therapies.
  • BTL did not direct content or influence the planning or implementation of the ASLMS 43rd Annual Conference.

AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio

Retrieved on: 
Tuesday, March 19, 2024
General Health, Alternative Medicine, Other Health, Health, Pharmaceutical, Face, Hyaluronic acid, Patient, Research, Restylane, System, Skin, NEXT, Consultant, Botulinum toxin, Neck

Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on March 27-29, 2024.

Key Points: 
  • Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on March 27-29, 2024.
  • “Galderma’s extensive activities at AMWC demonstrate our commitment to pushing the boundaries of injectable aesthetics, to anticipate and address tomorrow’s needs today.
  • The event is taking place in Room Prince Pierre on Wednesday March 27, 2024, from 2:00 to 4:00 PM CET.
  • Additional data spanning our leading neuromodulator portfolio, Alluzience and Azzalure, will be presented, as well as a new skin quality assessment scale and the AART-HIT™ approach for combining aesthetic products to maximize patient outcomes.

Grand opening of New Face Chicago MedSpa in River North Chicago enhances patient care

Retrieved on: 
Friday, March 8, 2024
Opus, Nursing, PDO, SKIN, Aesthetics, Social media, Face, Multimedia, MD, Medical director, Skin, Botulinum toxin, Skin care, Dental implant, Day, Pain management, Plasma, Health, Patient, Dentistry, Intravenous therapy, Beauty

CHICAGO, March 8, 2024 /PRNewswire-PRWeb/ -- March 6 2024 New Face Chicago MedSpa was launched on the concept of fully harmonizing the teeth and the face and to maintain full facial balancing by Dr. Irfan Atcha who has been replacing teeth with dental implants for over 25 years. It's a perfect way to have a full all inclusive modality of care from Teeth replacement, cosmetic Dentistry and all aspects of dental and facial aesthetics.

Key Points: 
  • Npaew Face Chicago MedSpa is one of a kind MedSpa where the concept of a dental implant center and cosmetic dentistry services know as New Teeth Chicago will tie into other facial aesthetic services such as Botox, Fillers, HydraFacial, Skin-resurfacing, micro-needling & many more with a youthful looking skin under New Face Chicago MedSpa.
  • It's all about harmonizing/balancing the teeth and the face for optimum patient care by adding facial aesthetic services.
  • New Face Chicago MedSpa is open 6 days a week including Saturdays and has convenient evening hours as well!
  • "With the launch of New Face Chicago Medspa we will be helping a lot of our existing patients and also the community of River North and the Chicagoland area" Mentions Dr. Atcha
    View original content to download multimedia: https://www.prweb.com/releases/grand-opening-of-new-face-chicago-medspa-...

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Retrieved on: 
Thursday, February 8, 2024
GLT, Growth, Certification, Prostate cancer, Palovarotene, Statute, Alagille syndrome, Primary biliary cholangitis, PDAC, Patient, FDA, FOP, Cabozantinib, Food, PBC, Botulinum toxin, Irinotecan, Ipsen, Phase, Acquisition, Environment, Albireo, Bank statement, Webcast, Carbon accounting, Core, Woman, Pharmaceutical industry

Ipsen ended the year with net cash of €65.1m, driven by solid free cash-flow generation of €710.9m.

Key Points: 
  • Ipsen ended the year with net cash of €65.1m, driven by solid free cash-flow generation of €710.9m.
  • Ipsen anticipates four commercial launches in 2024, following regulatory decisions for Onivyde in 1L PDAC in the U.S (H1), elafibranor in second-line PBC in the U.S. (H1) and in the E.U.
  • Ipsen has set the following financial guidance for FY 2024, which excludes any impact from potential late-stage external-innovation transactions:
    Total-sales growth greater than 6.0%, at constant currency.
  • The performance shown in this announcement covers the twelve-month period to 31 December 2023 (FY 2023) and the three-month period to 31 December 2023 (Q4 2023), compared to the twelve-month period to 31 December 2022 (FY 2022) and the three-month period to 31 December 2022 (Q4 2022), respectively, unless stated otherwise.

Wingderm® "Dual Innovation, Infinite Possibilities" Global Distributor conference was successfully held at IMCAS

Retrieved on: 
Monday, February 5, 2024
World Congress, Intelligence, PDO, Hair loss, Exhibition, Pigment, Botulinum toxin, Certificate, Infinite Possibilities

BEIJING, Feb. 5, 2024 /PRNewswire/ -- IMCAS World Congress 2024 was held in Paris, France from February 1st to 3rd.

Key Points: 
  • BEIJING, Feb. 5, 2024 /PRNewswire/ -- IMCAS World Congress 2024 was held in Paris, France from February 1st to 3rd.
  • On the first day, Wingderm® successfully held the "Dual Innovation, Infinite Possibilities" new device release conference for its signed distributors worldwide, along with Renuva® upgrade presentation and clinical application sharing session, which was a complete success.
  • Lasermach 2 is expected to be a highly competitive hair removal device in the next few years.
  • During the 3-day exhibition, Wingderm® showcased a lot of devices, with Lasermach 2 and the upgraded Renuva® garnering significant interest.

Wingderm® "Dual Innovation, Infinite Possibilities" Global Distributor conference was successfully held at IMCAS

Retrieved on: 
Monday, February 5, 2024
World Congress, Intelligence, PDO, Hair loss, Exhibition, Pigment, Botulinum toxin, Certificate, Infinite Possibilities

BEIJING, Feb. 5, 2024 /PRNewswire/ -- IMCAS World Congress 2024 was held in Paris, France from February 1st to 3rd.

Key Points: 
  • BEIJING, Feb. 5, 2024 /PRNewswire/ -- IMCAS World Congress 2024 was held in Paris, France from February 1st to 3rd.
  • On the first day, Wingderm® successfully held the "Dual Innovation, Infinite Possibilities" new device release conference for its signed distributors worldwide, along with Renuva® upgrade presentation and clinical application sharing session, which was a complete success.
  • Lasermach 2 is expected to be a highly competitive hair removal device in the next few years.
  • During the 3-day exhibition, Wingderm® showcased a lot of devices, with Lasermach 2 and the upgraded Renuva® garnering significant interest.

Global Medical Aesthetics Market to Surge with Technological Advancements and Male Participation - ResearchAndMarkets.com

Retrieved on: 
Friday, February 2, 2024
Pharmaceutical, Medical Supplies, Surgery, General Health, Health, Mental Health, Hospitals, Other Health, COVID-19, Growth, Male, Research, Clinic, Medical tourism, Dermatology, Filler (linguistics), Secrecy, Treatment, Botulinum toxin, Breast implant

The Global Medical Aesthetics Market is poised to experience substantial growth, reaching a projected market value of US$30.61 billion by 2028.

Key Points: 
  • The Global Medical Aesthetics Market is poised to experience substantial growth, reaching a projected market value of US$30.61 billion by 2028.
  • The report categorizes the market into segments such as Aesthetic Injectables, Energy-Based Devices, Physician-Dispensed Cosmeceuticals, and Breast Implants and Reconstructive Devices.
  • However, current trends, including a growing male demographic in medical aesthetics and the proliferation of new technology, are set to drive the market forward.
  • The report comprehensively outlines the dynamics, trends, and growth potential within the Global Medical Aesthetics Market, providing a valuable resource for understanding the competitive landscape and identifying opportunities in this booming field.

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Retrieved on: 
Thursday, January 18, 2024
AEON, Clavicle, Patient, Heart rate, Research, PTSD, Post-traumatic stress disorder, AB toxin, Stellate ganglion, OLE, Neck, DSM-IV codes, Torticollis, Safety, INA, DBP, Head, Botulinum toxin, Lidocaine, IND, Ptosis, FDA, Toxicity, Rat, SGB, Acute stress disorder, Data, Week, Anatomy, Pharmaceutical industry

IRVINE, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today presented new clinical and pre-clinical data for ABP-450 in treating cervical dystonia (CD) and posttraumatic stress disorder (PTSD) at TOXINS 2024, a leading conference held by the International Neurotoxin Association (INA) from January 17th - 20th at the Estrel Berlin in Berlin, Germany.

Key Points: 
  • ABP-450 did not appear to increase treatment-related TEAEs at any dose in the study.
  • These results support further investigation of ABP-450 as a treatment option for patients with CD and other movement disorders.
  • “We are excited to announce positive data from the 52-week OLE portion of the Phase 2 study of ABP-450 for CD.
  • The posters presented by AEON at the TOXINS 2024 conference can be accessed on the Events and Presentations page of the Company’s corporate website.

IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position

Retrieved on: 
Thursday, January 25, 2024
Research, Surgery, Clinical Trials, Biotechnology, Health, Cosmetics, Pharmaceutical, Retail, Science, Patient, Beauty, Human, SHAPE, World Congress, Kiss, READY, Boundary, Open, Education, Botulinum toxin, Physician, Pharmaceutical industry

Galderma will be sharing the latest updates from across its broad and unparalleled portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2024 from February 1-3, 2024, in Paris.

Key Points: 
  • Galderma will be sharing the latest updates from across its broad and unparalleled portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2024 from February 1-3, 2024, in Paris.
  • The updates reinforce Galderma’s leadership in aesthetic injectables and dermatological skincare.
  • “The breadth of our data and activities at IMCAS truly embodies our commitment to responding directly to the needs of healthcare professionals and patients.
  • Three symposia will highlight Galderma’s innovations and science as well as educational efforts to support the aesthetics community.

TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously

Retrieved on: 
Wednesday, January 17, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Cosmetics, Clinical Trials, Retail, Patient, Conference, Safety, Galderma, Botulinum toxin, READY, Pharmaceutical industry

Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines (frown lines) and lateral canthal lines (crow’s feet), either alone (single-area) or simultaneously.

Key Points: 
  • Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines (frown lines) and lateral canthal lines (crow’s feet), either alone (single-area) or simultaneously.
  • “We’re looking forward to sharing the latest updates from our world-leading injectable aesthetics portfolio at TOXINS 2024, particularly first data from our phase III READY-3 trial.
  • READY-3 is a phase III randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy, as measured by aesthetic improvement, of RelabotulinumtoxinA in patients with moderate to severe frown lines or crow’s feet, either administered as a single-area treatment or simultaneously on both frown lines and crow’s feet, when compared to placebo.
  • Results showed rapid onset of action, with over a third of patients seeing results on day 1 for frown lines (39%) and crow’s feet (34%), and demonstrated long duration of effect for six months.